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Abstract Fibrosis is the dramatic consequence of a dys-
regulated reparative process in which activated fibroblasts
(myofibroblasts) and Transforming Growth Factor b1
(TGFb1) play a central role. When exposed to TGFb1,
fibroblast and epithelial cells differentiate in myofibrob-
lasts; in addition, endothelial cells may undergo endothe-
lial-to-mesenchymal transition (EndoMT) and actively
participate to the progression of fibrosis. Recently, the role
of av integrins, which recognize the Arg-Gly-Asp (RGD)
tripeptide, in the release and signal transduction activation
of TGFb1 became evident. In this study, we present a class
of triazole-derived RGD antagonists that interact with
avb3 integrin. Above different compounds, the RGD-2
specifically interferes with integrin-dependent TGFb1
EndoMT in Endothelial Colony-Forming Cells (ECPCs)
derived from circulating Endothelial Precursor Cells
(ECPCs). The RGD-2 decreases the amount of membrane-
associated TGFb1, and reduces both ALK5/TGFb1 type I
receptor expression and Smad2 phosphorylation in ECPCs.
We found that RGD-2 antagonist reverts EndoMT, reduc-
ing a-smooth muscle actin (a-SMA) and vimentin
expression in differentiated ECPCs. Our results outline the
critical role of integrin in fibrosis progression and account
for the opportunity of using integrins as target for anti-
fibrotic therapeutic treatment.
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Abbreviations
ALK Activin receptor-Like Kinase
a-SMA Alpha-Smooth Muscle Actin
avb3 Alphavbeta3 integrin
ECFC Endothelial colony-forming cells
ECM Extracellular matrix
EndoMT Endothelial-to-mesenchymal transition
ERK1/2 Extracellular signal-regulated kinases 1/2
FN Fibronectin
MEndoT Mesenchymal-to-endothelial transition
RGD Arginine-glycine-aspartic acid
OPN Osteopontin
Smad Small mothers against decapentaplegic
homolog
TGF-b Transforming growth factor-b
VN Vitronectin
Introduction
Fibrotic disease encloses a wide array of different
pathologies both systemic such as systemic sclerosis (SSc)
and sclerodermatous graft versus host disease (Scl GVHD),
and organ-specific pathologies as idiopathic pulmonary
fibrosis (IPF), liver cirrhosis, and progressive kidney
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disease. Although the etiology of these fibrotic disorders
remains unexplained and may vary from disease to disease,
the common pathogenetic signs are the deposition of
extracellular matrix (ECM) synthesized by activated
myofibroblasts and the persistence of inflammation [1, 2].
High levels of cytokines, growth factors, and proteolytic
enzymes produced by activated macrophages and lym-
phocytes restrain the resolution process and fibrosis
expands gradually. Finally, matrix deposition rearranges
the tissue architecture, causing organ failure and patient
death. Thus, fibrotic diseases in their complex are life-
tethering diseases recognized to represent an important
health issue [3].
Transforming growth factorb1 (TGFb1) has been iden-
tified as the most important mediator in many types of
tissue fibrosis [4]. TGFb1 induces fibroblasts differentia-
tion into myofibroblasts providing collagen and ECM
protein deposition [5]. Experimental studies have provided
evidences that myofibroblasts not only originate from res-
ident fibroblasts, but also derive from the transdifferentia-
tion of epithelial cells, endothelial cells, and bone marrow-
derived cells [6, 7]. Endothelial cells and bone marrow-
derived endothelial cells, when exposed to TGFb1,
undergo endothelial–mesenchymal transition (EndoMT).
As a consequence, endothelial cells lose their biological
characteristic of the endothelial phenotype, acquire typical
mesenchymal features, and concurrently express typical
markers of myofibroblastic differentiation: a-smooth
muscle actin (a-SMA), vimentin, and collagen production
[8].
TGFb1 is produced as inactive pro-peptide by different
types of inflammatory cells. The mature cytokine is
exposed in the extracellular space non-covalently associ-
ated to a latency-associated peptide (LAP), and the LAP–
TGFb1 pro-peptide forms a homodimer complex. This
complex, which prevents the interaction of the mature
cytokine with its receptors, is stored in the extracellular
space, closely associated to the cell membrane and boun-
ded to specific latent TGFb1 binding proteins (LTBP).
LTBP fixes the system in association to fibrillin-1 and
fibronectin. The release of the non-covalently bounded
mature TGFb1 from the LAP complex occurs by the action
of proteases (matrix metalloproteases MMP, thrombin, and
plasmin) or by the effect of environmental condition
changes (pH, pO2, or temperature) [9, 10]. Moreover, in
the recent years, the role of av integrins in TGFb1 release
from the LAP complex during fibrotic disease progression
became evident [11, 12]. It has been demonstrated that av
integrins recognize the tripeptide Arg-Gly-Asp (RGD)
sequence of the LAP, and the integrin binding induces a
stretch of the complex and a mechanical release of the
active TGFb1 [13]. In addition, it is known that av inte-
grins might function as docking site for MMPs contributing
to the protease-dependent release of TGFb1. Thus, the
maintenance of high levels of TGFb1 exacerbates tissue
damages and outlines the important role of integrins in the
instauration and progression of fibrosis [14, 15].
In this study, we present a novel class of avb3 RGD
antagonists that interfere with integrin-dependent release of
TGFb1 from LTBP complex. Interestingly, we found that
the RGD-2-integrin antagonist counteracts the TGFb1-in-
duced myofibroblast differentiation of endothelial precur-
sor cells (ECPCs) by interfering, in these cells, with the
autocrine loor of TGFb1 activation.
These findings may suggest an innovation in anti-fi-
brotic treatment. The common anti-fibrotic treatments are
based, so far, on the use of corticosteroids and immuno-
suppressant drugs. These drugs may retard, but do not
arrest, the disease progression. Thus, the cooperation
between anti-fibrotic available drugs and novel RGD
antagonists might contribute to the inhibition of the vicious
cycle, led by TGFb1, underlying the disease progression.
Results
RGD triazole-derived avb3 antagonists
RGD triazole-derived antagonists of the avb3 integrin
receptor were synthesized in our laboratory as previously
described [16]. Solid-phase assay was used to test the
ability of RGD ligands to compete with 125I-echistatin for
the binding to avb3 integrin receptor. We found that RGD-
1 compound showed an IC50 value of 2.1 ± 1.3 lM, while
compound RGD-2 showed an IC50 of 37 ± 11 nM. In
contrast, the IC50 value of RGD-3 compound was found to
be[10 lM, addressing for a less active antagonistic effi-
cacy toward avb3 receptor (Table 1).
Effect of the triazole RGD antagonists on ECPCs
adhesion
ECPCs, isolated from human umbilical cord blood (UCB),
were characterized using flow cytometry assay by surface
expression of endothelial cell-specific antigens: Ulex
europaeus I agglutinin (Ulex), Platelet Endothelial Cell
Adhesion Molecule-1 (PECAM-1/CD31), Vascular
Endothelial Growth Factor Receptor 2 (VEGFR-2/KDR),
Phagocytic Glycoprotein-1 (CD44), integrin b1-chain
(CD29), and integrin heterodimers avb3 (Fig. 1a). ECPCs
were monitored throughout the experimental procedures
for avb3 integrin expression (Fig. 1b), the maintenance of
endothelial phenotype (Fig. 1c), and the in vitro tube for-
mation ability (Fig. 1d). Sub-confluent cultures of ECPCs
between the 3rd and 6th passage were exposed to different
doses (10, 1, 0.1, and 0.01 lM) of three different triazole
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RGD antagonists and allowed to adhere to vitronectin (VN)
for 1 h. At the end of the incubation, non-adherent cells
were removed by a gentle wash with PBS. We found a
40 % of inhibition of ECPCs adhesion to VN for RGD-1
compound at 10 lM, whereas lower concentrations of this
compound showed a weak inhibition of cells adhesion. The
RGD-2 compound clearly inhibited ECPCs adhesion to VN
in a dose-dependent manner, ranging from 80 % of inhi-
bition at 10 lM to 20 % at 10 nM. Finally, RGD-3 com-
pound did not significantly inhibit ECPCs adhesion to VN
(Fig. 1e). To further evaluate RGD-2 inhibitory activity
toward different RGD containing substrata, ECPCs cells
were exposed to RGD-2 compound at different doses
before adhesion to osteopontin (OPN), Fibronectin (FN),
and Matrigel. We found that RGD-2 antagonist showed a
dose-dependent inhibition of ECPCs adhesion to OPN from
75 % at 10 lM to 25 % at 10 nM. In contrast to this,
inhibition of adhesion to FN and Matrigel was very weak.
Matrigel was used as negative control since it is composed
by laminin, collagen IV, nidogen/enactin, and proteogly-
can, which are ligands for other non-RGD families of
integrin receptors (laminin-type and collagen-type)
(Fig. 1f).
Effect of RGD-2 triazole compound on avb3
expression in TGFb1-stimulated ECPCs
ECPCs were exposed to RGD-2 compound at 1 lM and/or
TGFb1 at 1 nM/ml for 24 h. Here we found an
overexpression of b3 subunit mRNA in TGFb1-treated
ECPCs, while the co-treatment with the RGD-2 antagonist
did not show any b3 subunit increase (Fig. 2a). Along with
this, we found that protein expression of avb3 receptor was
increased, in TGFb1 treated ECPCs, while treatment with
RGD-2 antagonist abrogates TGFb1, inducing avb3
expression in ECPCs (Fig. 2b).
Effect of RGD-2 antagonist on TGFb1 signal
transduction pathway and TGFb1 expression
on ECPCs cell membrane
In order to evaluate the signal transduction activation of
TGFb1 pathway in ECPCs cells, we investigated ALK-5
expression and SMAD phosphorylation after TGFb1 and/
or RGD-2 treatment. We observed that 24 h treatment with
TGFb1 induces the increase of ALK-5 expression also in
the presence of the RGD antagonist (Fig. 3a). Moreover,
when we evaluated SMAD2 phosphorylation, we found an
increase in Phospho-SMAD2 in TGFb1-treated cells, while
in RGD-2/TGFb1-co-treated cells, SMAD2 phosphoryla-
tion was similar to untreated cells (Fig. 3b). We, also,
evaluated the effect of RGD-2 antagonist on TGFb1 acti-
vation in ECPCs. Cells were exposed for 24 h to exoge-
nous TGFb1 (1 ng/ml). After the removal of the medium,
cells were allowed to grow for the next 24 h in a standard
medium. At the end of the second incubation, ECPCs were
lysed directly in tissue culture plates and processed for
western blotting analysis. We found high levels of
Table 1 Inhibition of 125I-echistatin-specific binding to purified human integrin proteins avb3 by triazole-containing RGD peptidomimetics
Triazole-derived RGD antagonist Structure Specific binding versus avb3, IC50 (lM)
RGD-116
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membrane-associated TGFb1, in TGFb1-treated cells,
compared to untreated cells. While the treatment with
RGD-2 antagonist (1 lM) alone did not modify TGFb1
levels, the co-treatment with TGFb1 and RGD-2 antagonist
reduced significantly the expression of endogenous TGFb1
to the levels found in untreated cells (Fig. 3a).
RGD-2 antagonist reverts TGFb1-induced EndoMT
in ECPCs
We found that TGFb1 significantly increased the expres-
sion of a-SMA and vimentin in ECPCs together with a
significant switch to an elongated morphology. Upon the
morphological observation of ECPC-treated cultures, we
found that TGFb1-treated cells present a fibroblast-like
morphology, as expected, but this change was absent when
the cells were treated with the RGD antagonist and TGFb1,
and the culture morphology was slightly similar to that of
untreated cells (Fig. 4a). RGD-2 antagonist-treated cells
express a-SMA and vimentin at levels similar to the
untreated cells. Thus, the treatment with the RGD-2
antagonist in association with TGFb1 significantly reduced
the expression of mesenchymal markers of EndoMT, as
demonstrated in western blotting analysis and in
Fig. 1 RGD triazole-derived
antagonists on ECPCs adhesion
to RGD containing substrata.
a Flow cytometric analysis of
surface antigens expression in
freshly isolated ECPCs
(percentage of positive cells).
Biological properties of ECPCs,
b flow cytometric analysis of
avb3 integrin expression of
cultured cells, c contrast
microscopy images of ECPCs
growing cultures, and d contrast
microscopy images of ECPCs
tube formation. e Inhibition of
adhesion of ECPCs to VN in the
presence of different
concentration of different RGD
triazole antagonists (RGD-1,
RGD-2, and RGD-2 triazole
compounds), and f inhibition of
adhesion of ECPCs to Matrigel,
FN, and OPN in the presence of
different concentrations of
RGD-2 antagonist.
Representative results from
three different experiments.
Values represent the
mean ± SD
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immunofluorescence (Fig. 4b). Next, we evaluated MAPK
pathway activation after exposure to TGFb1 and to the co-
treatment TGFb1/RGD-2. We found that ERK1/2
phosphorylation increases in ECPCs after treatment with
exogenous TGFb1, and that the co-treatment with TGFb1/
RGD-2 inhibited ERK1/2 phosphorylation (Fig. 4c). To
explore the effect of RGD antagonist on ECPCs biological
behavior during TGFb1-induced EndoMT, we evaluated
the invasive activity, wound healing ability, and in vitro
angiogenesis of cells exposed to exogenous TGFb1 and
RGD-2 antagonist. We found a significant reduction in
ECPCs invasion through Matrigel after treatment with
exogenous TGFb1. Significant but less intense reduction in
ECPCs invasion was found after treatment with RGD-2
antagonist alone, while the treatment with RGD antagonist
together with TGFb1 partially restored the originally
migratory phenotype of the cells (Fig. 4d). Moreover, it is
widely recognized that ECPCs exert a fundamental role the
healing process, restoring the physiological function of
vascular network. We found that, accordingly with previ-
ous finding, ECPCs cells exposed to TGFb1 lose their
wound healing potency, while ECPCs cells treated with
TGFb1 and RGD-2 antagonist almost completely recover
their ability to heal the wound. Finally, it is known that
ECPCs are characterized by their high proliferation rate
and by their ability to give rise to capillary network in the
in vitro angiogenic assay; thus, ECPCs were seeded on
Matrigel in the presence of TGFb1 and/or the RGD-2
antagonist. After 24 h incubation, the number of branches
per field was counted. We observed a significant decrease
in the number of branches of ECPCs treated with TGFb1 as
compared to untreated cells. The co-treatment with the
RGD antagonist partially restored the ECPCs ability to
form a capillary network (Fig. 4f).
Discussion
In the present study, we investigated the role of different
triazole-derived RGD antagonists in the TGFb1 loop of
ECPCs activation during endothelial–mesenchymal transi-
tion (EndoMT). Above the different triazole-derived
compounds, we found that the stereochemistry of the tyr-
osine/phenyl moiety was crucial for the antagonistic effi-
ciency of the compounds. The guanidine substitution, in
the arginine mimetic portion of the molecule with the
aminopyridine moiety, increased the binding affinity
toward avb3 integrin. Integrin avb3 specifically recognizes
the Arg-Gly-Asp (RGD) tripeptide present in the sequence
of different extracellular matrix proteins. Although ECPCs
express the integrin receptors avb3 and a5b1 which rec-
ognize RGD extracellular matrix proteins as vitronectin
(VN), fibronectin (FN), and osteopontin (OPN), in our
conditions, ECPCs adhesion to FN was not inhibited by the
RGD antagonist; this result might be explained outlining
two observations. The first is that avb3 and a5b1, even
Fig. 2 Effect of RGD-2 on avb3 expression in ECPCs. Integrin avb3
expression in ECPCs after 24 h treatment with exogenous TGFb1
(1 ng/ml) and/or 1 lMRGD-2 antagonist: amRNA forav,b3 subunits,
andGAPDH, andbavb3 protein expression and densitometric analysis
Fig. 3 Effect of RGD-2 antagonist on TGFb1 signal transduction
pathway and TGFb1 expression on ECPCs cell membrane. a TGFb1
and ALK-5 were evaluated in ECPCs exposed for 24 h to exogenous
TGFb1 and/or RGD-2 triazole and for additional 24 h to fresh
standard medium. b Protein expression and densitometric analysis of
PhosphoSMAD2 (pSMAD2) evaluated in ECPCs exposed to exoge-
nous TGFb1 and/or RGD-2 for 1 h. All experiments were conducted
at least three times. Values represent the mean ± SD. *P\ 0.05
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though recognize the RGD tripeptide sequence, display
specific binding affinity for a given ligand depending also
on few essential amino acid residues surrounding the
binding site pocket of the integrin receptor itself; thus, VN
and OPN exhibit higher binding affinity for avb3 integrin,
while FN exhibits high binding affinity to a5b1 integrin
[17]. The second observation is that different RGD antag-
onist might display a different affinity to the same integrin
receptor depending on those interactions with receptor
amino acid residues close to the binding pocket [18].
Many clinical and experimental observations confirm
the key role of TGFb during the instauration and the per-
sistence of the fibrotic disease, mostly through the auto-
crine loop of TGFb activation [19]. The TGFb belongs to a
ligand superfamily comprising the three forms of TGFbs
(TGFb1, TGFb2, and TGFb3), Activins, BMPs (Bone
Fig. 4 RGD-2 antagonist reverts TGFb1-induced EndoMT in
ECPCs. a Contrast microscopy representative images of ECPCs after
24 h treatment with TGFb1 and/or RGD-2 compound, morphological
changes. b Expression of EndoMT markers of mesenchymal differ-
entiation; ECPCs were exposed to exogenous TGFb1 (1 ng/ml) and/
or 1 lM RGD-2 antagonist for 24 h, and a-SMA and vimentin
expression were evaluated. Upper panel: western blotting for a-SMA
and vimentin; lower panel: representative immunofluorescence
images for a-SMA. c TGFb1-induced phosphoERK1/2 activation,
ECPCs were exposed to different treatments for 24 h and lysed.
d Invasiveness through Matrigel of ECPCs after 24 h treatment with
exogenous TGFb1 (1 ng/ml) and/or 1 lM RGD-2 antagonist; for
quantification, migrated cells were counted in six randomly chosen
fields for each filter. e Wound healing assay of ECPCs after 24 h
treatment with exogenous TGFb1 (1 ng/ml) and/or 1 lM RGD-2
antagonist; the degree of healing was quantified by measuring the
distance between opposing edges of the wound. Four wound/
treatment and three measurements/wound were taken. f In vitro tube
formation of ECPCs after 12 h treatment with exogenous TGFb1
(1 ng/ml) and/or 1 lM RGD-2 antagonist; for quantification, the
number of branches per field was evaluated at 40 magnifications, in
four different fields. Data were obtained from three independent
experiments. Percentage of inhibition was expressed compared to
untreated cells. Values represent the mean ± SD. *P\ 0.05,
**P\ 0.01
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Morphogenetic Proteins), and GDFs (Growth and Differ-
entiation Factors). In general, TGFb superfamily ligands
bind to a complex of TGFb type I and TGFb type II serine/
threonine kinase receptors. In the absence of stimuli, the
homodimers of type I, also known as Activin receptor-Like
Kinase (ALK), and of type II receptors are expressed on the
cell surface in a separate form [20].
Upon recognition of the TGFb1 by the type II receptor,
whose function is to present the ligand, the activation of the
downstream signal requires the association of the type
I/type II receptors in a heterotetrameric complex and the
transphosphorylation of the type I receptor/ALK by the
serine/threonine kinase activity of type II receptor. Then,
the type I receptor transfers the signal into the nucleus by
the phosphorylation of the SMAD proteins. The combina-
tion of different type II/type I tetrameric receptors deter-
mines the activation of different downstream signaling
pathways, in response to the same ligand [21].
In endothelial cells, soluble TGFb1 interacts with type II
receptor (TGFb1RII) and, among the different types of
ALKs, ALK-5 phosphorylation induces the activation of
SMAD2/3 pathway involved in endothelial cells inhibition
of proliferation/migration and in the promotion of the
extracellular matrix proteins synthesis, while ALK-1
phosphorylation induces the activation of SMAD1 and
SMAD5 pathways that leads to endothelial cells migration
and proliferation [22].
ECPCs might contribute substantially to the overex-
pression of TGFb that forces the maintenance of a dys-
regulated reparative process [23]. Thus, it has been
demonstrated, in lung fibroblasts, that TGFb1 induces
overexpression of avb3 integrin which potentiates TGFb1
responsiveness of the cells [24]. Although our findings are
not completely exhaustive, indicate that ALK-5 expression
is upregulated by exogenous TGFb1 treatment, but that the
downstream activation of signal transduction, through the
ALK-5 receptor, may depend on avb3-mediated release of
endogenous TGFb1. Moreover, it is known that the type I
receptor, in addition to Smad 2/3 protein phosphorylation,
activates other non-Smad signaling pathways involving
ERK1/2, TGF-b-activated kinase-1 (TAK-1), JNK, p38,
Rho GTPases, and the PI3 K–AKT pathways [25]. We
observed that while the interaction between the RGD
antagonist and the integrin receptor did not induce any
downstream signal transduction activation, the co-treat-
ment with triazole RGD antagonist reduced significantly
the ERK1/2 activation induced by TGFb1.
TGFb1, being the most important mediator in tissue
fibrosis, is recognized to induce in vitro the endothelial–
mesenchymal transition in endothelial cells and circulating
endothelial precursor cells [26–29]. Despite other authors
demonstrated that a cyclic RGD antagonist enhances
in vitro and in vivo vascularization in a model of EPCs
[30], we found a mild but significant reduction in the
capillary formation after the treatment with the triazole
RGD antagonist. This result was in agreement with our
previous observation on mature human umbilical vein
endothelial cells (HUVEC) [31]. We suggest that our
findings depend by the contribution of two main different
mechanisms of interaction between the RGD-2 antagonist
and the avb3 receptor. The first is the direct role that
integrin avb3 exerts in endothelial cells invasion and
in vitro angiogenesis, resulting in a reduction in invasion
and angiogenesis operated by the linear triazole pep-
tidomimetic antagonists alone. The second is the interfer-
ing effect of RGD-2 antagonist in the TGFb1/avb3
crosstalk that reverts EndoMT in ECPCs and exerts a
fundamental anti-fibrotic and pro-resolution effect. It has to
be noted that the interest in the synthesis and identification
of bioactive RGD antagonists originates from the need in
improving anti-angiogenic treatment of cancer, since the
outcomes of drugs against vascular endothelial growth
factor and relative receptors have shown a partial lack of
efficacy both in vitro and in vivo [32–34]. The av RGD
mimetic cyclic pentapeptide, Cilengitide (EMD 121974),
has been identified as the first synthesized anti-angiogenic
small molecule, and its effect on endothelial cells has been
demonstrated [35]. Cilengitide showed encouraging activ-
ity in patients with glioblastoma and melanoma, and is
currently used in clinical trials [36, 37]. In contrast to this,
other authors found that Cilengitide enhances angiogenesis,
and promotes tumor growth and cell invasion [38]. In our
model, despite the strong effect of the RGD triazole on the
inhibition of cell adhesion, we found a weak effect on the
inhibition of invasion and angiogenesis that might be
explained by the specific and unique activity of this linear
triazole RGD antagonist against the avb3 receptor. Along
with this, we should take into account that invasiveness and
tube formation assays are performed on Matrigel substrate,
against which the RGD triazole effect is not specific, and
that the spatial occupation of the integrin receptor binding
site by the RGD triazole may not be sufficient to overcome
integrin redundancy in invasiveness and tube formation
processes. Indeed, during the ECPCs invasion and migra-
tion process, many interactions between ECM and other
integrin receptors, as a5b1 and a6b1, have been found to
be involved [39–41], as well as many interactions between
ECM and cell-derived proteases. Thus, the avb3 integrin
receptor activity might be only partially involved in ECPCs
invasion and tube formation [42].
In a fibrotic lesion, TGFb1 is released by activated
fibroblasts and macrophages, or endothelial cells them-
selves, and induces a local overload of TGFb1 driving to
stroma activation. Circulating precursor endothelial cells,
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recruited by pro-inflammatory cytokines, differentiate in
activated fibroblasts, and endogenous TGFb1 amplifies the
fibrotic vicious circle. To date, the therapeutic interven-
tions on fibrotic diseases are the use of anti-inflammatory
mediators, immunomodulatory drugs, or agents that
directly block TGFb1 activity, such as specific antibody.
Unfortunately, anti-inflammatory treatment only retards
but does not resolve fibrosis, while TGFb1 antibody might
compromise important activity of this cytokine in other
tissues [43]. Our findings are in agreement with the
importance of integrin involvement in fibrosis [44, 45].
Here, we introduced a new synthesized non-peptidic
compound with anti-fibrotic properties in an in vitro model
of tissue fibrosis. This RGD antagonist not only prevents
the avb3-mediated TGFb1 release dampening the auto-
crine loop of ECPCs activation, but also promotes a mes-
enchymal-to-endothelial transition (MEndoT), reverting
the TGFb1-mediated phenotype of activated endothelial
cells. It should be noted that a avb6 monoclonal antibody
is involved in a phase 2 study for idiopathic pulmonary
fibrosis (STX-100, NCT01371035) [46]. This observation
confirms the need of further investigations to delineate the
role that integrin antagonists might have in the designing of
anti-fibrotic therapies. On the whole, our results might
support the hypothesis for an EndoMT reversion mediated
by RGD antagonist. Exogenous TGFb1, released in the
fibrotic microenvironment, induces avb3 receptor overex-
pression in ECPCs. The presence of high levels of avb3
receptors enhances the release of active TGFb1 from LAP.
Endogenous ECPCs-derived TGFb1 interacts with its
receptors on ECPCs themselves promoting EndoMT
(Fig. 5a). The RGD antagonist, by occupying the binding
site of the avb3 receptor, reduces the traction exerted by
the heterodimer on the RGD sequence of the LAP, thus
reducing endogenous TGFb1 release and dampening the
autocrine loop of TGFb1 activation (Fig. 5b).
Materials and methods
Synthesis of triazole-based non-peptide RGD
peptidomimetic
The triazole-based RGD ligand was achieved using the
click chemistry by combining azide and alkyne in the Cu-
catalyzed azide–alkyne cycloaddition, followed by acid-
mediated hydrolysis of the protecting groups of side chain
isosteres [16, 31, 47]. Three bioactive compounds were
selected starting from a group of avb3 integrin ligands.
Solid-phase integrin binding assay
The inhibition of 125I-echistatin-specific binding to avb3
integrins by RGD antagonists was evaluated as previously
reported [47]. Briefly, 125I-echistatin with a specific activ-
ity of 2000 Ci/mmol was purchased from Perkin Elmer,
and integrin avb3 from human placenta was purchased
from Millipore. Purified avb3 integrin (Millipore) was
diluted in coating buffer [20 mM Tris (pH 7.4), 150 mM
NaCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2] at
concentrations of 500 or 1000 ng/mL. Aliquots of avb3
integrin (100 lL/well) were added to a 96-well plate (Perkin
Elmer), and plates were incubated overnight at 4 C, fol-
lowed by washings with blocking/binding buffer [20 mM
Tris (pH 7.4), 150 mM NaCl, 2 mM CaCl2, 1 mM MgCl2,
1 mM MnCl2, and 1 % BSA], and then incubated at room
temperature for an additional 2 h. After two washing with
the same buffer, aliquots of 125I-echistatin (0.05 nM) were
added to each well with different concentrations of RGD
compounds (from 0.01 to 100 nM). Non-specific binding
was defined as 125I-echistatin bound in the presence of an
excess (1 lM) of unlabeled echistatin. After 3 h incubation
at RT, plates were washed three times with blocking/
binding buffer and counted in a Top-Count NXT micro-
plate scintillation counter (Perkin Elmer) using 200 lL/
Fig. 5 Hypothesis for molecular mechanism of RGD antagonist
EndoMT reversion in ECPCs. a Mechanism of TGFb1-induced
EndoMT and avb3-mediated autocrine loop of TGFb1 release in
ECPCs. b Role of RGD-2 triazole antagonist in dampening autocrine
loop of TGFb1 activation
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well of MicroScint-40 liquid scintillation (Perkin Elmer).
Data are shown as mean ± SD from three independent
experiments. IC50 values were determined by fitting
binding inhibition data by non-linear regression using
GraphPad Prism 4.0 Software Package (GraphPad Prism,
San Diego, CA).
Isolation of endothelial colony-forming cells
and culture conditions
Endothelial Colony-Forming Cells (ECPCs), a subpopula-
tion of Endothelial Precursor Cells (EPCs), were isolated
from[50 ml human umbilical cord blood (UCB) of health
newborns, as described [48, 49], for the banking estab-
lished by the Umbilical Cord Bank of Careggi Hospital
(Florence, Italy) after maternal informed consent in
accordance with the Declaration of Helsinki and in com-
pliance with Italian legislation. ECPCs were analyzed for
the expression of surface antigens (CD31, CD44, CD29,
ULEX, KDR, and avb3) and were grown in complete
EGMTM-2 BulletKitTM (CC-3162 Lonza) with 10 % Fetal
Bovine serum (FBS) (Hyclone). Confluent cell cultures
were propagated every 3 days, for no more than 10 pas-
sage, and seeded on gelatin-coated tissue culture plates at a
density of 5 9 105 cells/cm2 in a 5 % CO2 humidified
incubator at 37 C. ECPCs cultures, grown to subconflu-
ence, were treated for 24 h with 1 ng/mL of hrTGFb1
(Peprotech), or triazole RGD antagonist (1 lM), or both in
EGM-2 medium (Endothelial cells Growth Medium-2) in
the absence of growth factors and in the presence of 2 %
FBS (Fetal Bovine Serum). In some experiments, treated
cells were exposed to fresh medium for an additional 24 h
treatment before protein extraction.
Flow cytometric analysis
Cells were collected using Accutase (a trypsin-free cell
dissociation buffer from Sigma) and resuspended in PBS
with 1 % BSA (FACS buffer). After blocking, cells were
incubated with 1 lg/50 lL of primary antibody [anti-
CD31, anti-CD44, or anti-CD29 (BD Biosciences
PharMingen); anti-ULEX (Vector Laboratories), anti-KDR
(RELIATech), or anti-avb3 (Millipore)] for 1 h at 4 C,
followed by 1 h incubation with FITC-conjugated sec-
ondary antibodies (Santa Cruz). After extensive washes
using FACS buffer, cells were analyzed at 488 nm on the
flow cytometer FACScan system (BDFACSCanto).
Cell adhesion assay
Sub-confluent cultures of ECPCs between the 3rd and 6th
passage were used for the inhibition of adhesion assay.
Plates (96 wells) were coated with MatrigelTM Matrix (BD
Biosciences) (10 lg/ml), vitronectin (10 lg/mL), fibro-
nectin (1 lg/mL), or osteopontin (0.5 lg/mL), by over-
night incubation at 4 C. Plates were washed with PBS and
then incubated at 37 C for 1 h with PBS-1 % BSA. After
being washed, ECPCs were counted, suspended in serum-
free medium, and exposed to triazole RGD antagonists
(final concentration was 0.01, 0.1, 1.0, or 10 lM) at 37 C
for 30 min to allow for the ligand-receptor equilibrium to
be reached. ECPCs were plated ((4–5)104 cells/well) and
incubated at 37 C for 2 h. All the wells were washed with
PBS to remove the non-adherent cells, and 0.5 % crystal
violet solution in 20 % methanol was added. After 2 h of
incubation at 4 C, plates were examined at 540 nm in an
ELX800 counter (Bio TEK Instruments). Data were
expressed as percentage of inhibition compared to
untreated cells. Experiments were conducted in triplicate
and were repeated at least three times [49].
RNA extraction and RT-PCR
Total RNA was extracted from ECPCs using RNAgents
(Total RNA Isolation System, Promega, Madison, WI) and
quantified spectrophotometrically. A volume of 500 ng of
RNA was then retrotranscribed using ImProm-II reverse
transcriptase (Promega, Madison, WI). Aliquots of 2 ll of
the cDNA were used for PCR amplification. The specific
primers used for the identification of human av, b3, and
GAPDH were designed according to published human
cDNA sequences in the Genbank database, using FastPCR
software [50]: av (forward50-CTA TGA GCT GAG AAA
CAA TGG TCC-30 and reverse 50GCT GCT CCC TTT
CTT GTT CTT C-30690-bp product); b3 (50- GGG GAC
TGCC TGT GTG ACT C-30 and reverse 50-CTT TTC GGT
CGT GGA TGG TG-30 610-bp product); GAPDH (for-
ward: 50-ACC ACA GTC CAT GCC ATC AC-30 and
reverse: 50-TCC ACC ACC CTG TTG CTG TA-30, 452-bp
product). PCR was carried out on a Perkin Elmer Thermal
cycler. Ten microliters of each PCR products were visu-
alized after electrophoresis in a 2 % agarose. cDNA
products were evaluated on the basis of a standard PCR
marker (Promega) and quantified by densitometric analysis
using ImageJ software (NIH).
Western blotting
ECPCs monolayers were lysed on ice in radioimmuno-
precipitation assay buffer [50 mmol/L Tris–HCl (pH 7.5),
150 mmol/L NaCl, 1 % Triton X-100, 2 mmol/L EGTA,
1 mmol/L sodium orthovanadate, 1 mmol/L phenyl-
methane sulfonyl-fluoride, 10 lg/mL aprotinin, and 10 lg/
mL leupeptin]. Samples were resolved by SDS-PAGE and
transferred to a nitrocellulose membrane (Millipore, Bil-
lerica, MA). The blots were incubated in Bløk-FL
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blocking buffer at room temperature and probed with pri-
mary antibodies and appropriate secondary antibodies for
infrared fluorescence detection. Membranes were visual-
ized by Odyssey Imager which quantifies protein amount
proportional to infrared signal. Antibodies used for western
blotting were as follows: anti-TGFb1 (orb11468, Byorbit);
anti-Alk5/TGFbRI (GTX102784, Genetex); anti-Phos-
phoERK1/2 and anti ERK1/2 (9101 and 9102, Cell Sig-
nalling); anti a-SMA (A2547, Sigma); anti-vimentin
(V6630, Sigma); and anti-Phospho SMAD2 and anti-
SMAD2/3 (3101 and 3102, Cell Signalling). Human anti-
b-tubulin (Millipore 05-661) was used as a loading control.
Fluorescent goat anti-mouse and anti-rabbit secondary
antibody were conjugated to AlexaFluor-680 and
AlexaFluor-750, respectively (Invitrogen). Fluorescent
signals of protein bands were recorded at 700 nm (mouse)
and 800 nm (rabbit); in some experiments, the quantifica-
tion of immunoblotting bands was performed by densito-
metric analysis with Odyssey infrared imaging system (Li-
COR Biosciences, USA).
Immunofluorescence
ECPCs cells were cultured on 25-mm coverslips pre-coated
with 10 lg/ml of VN. After 24 h of incubation, in the
presence of TGFb1, RGD-2 antagonist, or both, in com-
plete EGM-2 medium, cells were washed in PBS, were
fixed in 4 % paraformaldehyde, and membranes were
permeabilized in 0.1 % Triton X-100 solution. Coverslips
were incubated in blocking solution (PBS supplemented
with 4 % BSA and 1 % horse serum) and then incubated at
4 C overnight with anti-a-SMA primary antibodies,
washed and incubated for 1 h with goat anti-mouse
AlexaFluor-488 antibodies (Invitrogen). Cell nuclei were
counterstained with DAPI (1 lg/ml for 10 min at 37 C).
Following two washes in PBS, coverslips were mounted
with propylthiogallate on glass slides, and the cells were
observed with an inverted confocal Nikon Eclipse TE2000
microscope equipped with a 960S-Fluor oil immersion
lens.
ECPCs migratory activity
In order to investigate the migratory activity of ECPCs,
Boyden chamber assays were performed using Millicell
cell culture inserts (Millipore 8-lm pore size, 12 mm
diameter). A 3D barrier of 50 lg/cm2 of Matrigel was
stratified on the filters, and ECPCs were loaded into the
upper compartment (5 9 104 cells/well) in 400 ll of
complete EGM-2 containing TGFb1, RGD-2 antagonist, or
both and placed into 24-well culture dishes containing
600 ll of EGM-2 complete medium. After overnight
incubation at 37 C, non-invading cells were removed
mechanically using cotton swabs, and micro-porous
membrane containing the invaded cells was fixed in 96 %
methanol and stained with Diff-Quick staining solutions.
Migratory activity was evaluated by counting the cells
which migrated toward the lower surface of the filters (six
randomly chosen fields for each filter).
In vitro tube formation assay
The effects of TGFb1, RGD-2 antagonist, or both on the
ability of ECPCs to reorganize and differentiate into cap-
illary-like network were assessed, thereby Matrigel mor-
phogenesis assay. Briefly, 50 ll of Matrigel (1 mg/ml) was
added into wells of a 96-well plate and polymerized for 1 h
at 37 C. After 24 h of incubation, in the presence of
TGFb1, RGD-2 antagonist, or both, in complete EGM-2
medium, cells were washed once with PBS, harvested by
trypsinization, and collected by centrifugation. Then, cells
were resuspended in 200 ll of EGM-2 complete medium
and placed into Matrigel-coated wells (6 9 105 cells/well).
After 12 h incubation on Matrigel at 37 C, the plates were
photographed under a phase contrast microscope. The
degree of tubule formation was quantified by counting the
branching points in four randomly chosen fields from each
well [51].
Wound healing assay
Cell migration was evaluated by an in vitro wound healing
assay. Cells were grown at 80–90 % confluence in 35-mm
dishes; the cell layer was wounded with a sterile 200-ml
pipette tip and incubated in 0.1 % FBS culture medium for
24 h. The wound was observed after 18 h, and pictures
were taken using phase contrast microscope. The degree of
healing was quantified by measuring the distance between
opposing edges of the wound. Four wound/treatment and
three measurements/wound were taken. Percentage of
inhibition was expressed compared to untreated cells.
Statistical analysis
Results were analyzed using a 2-tailed Student’s t test to
assess statistical significance. Statistical differences are
presented at probability levels of P\ 0.05 or P\ 0.01.
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